Introduction {#S1}
============

Depression is a common (30 -- 50%) side-effect of interferon (IFN)-alpha treatment of hepatitis C virus (HCV) infection and melanoma, and might compromise the effectiveness of therapy \[[@R1]\]. Experimental and clinical data suggested that disturbances of tryptophan (TRP) metabolism might contribute to the development of IFN-alpha--associated depression \[[@R2]\]. IFN-alpha transcriptionally activates indoleamine 2,3-dioxygenase (IDO) \[[@R3]\], the rate-limiting enzyme of TRP conversion into kynurenine (KYN), the major (90%) non-protein pathway of TRP metabolism \[[@R4]\]. Up-regulation of TRP -- KYN metabolism limits availability of TRP as a substrate for minor pathway of TRP metabolism, i.e, biosynthesis of serotonin and other methoxyindoles: N-acetyl serotonin and melatonin \[[@R4]\]. In addition to serotonin deficiency, suggested as one of the mechanisms of depression \[[@R4],[@R5]\], increased formation of KYN and its neuroactive derivatives contribute to mechanisms of depression as well \[[@R6],[@R7]\]. Production of IFN-gamma (IFNG), the strongest among interferons inducer of IDO, is encoded by polymorphic IFNG (+874) T/A gene \[[@R8]\]. We reported the association of high producer (T) allele of IFNG +874) gene with increased risk of IFN-alpha associated depression \[[@R9]\]. Our observation suggested the association between IDO activity and risk of depression. The present study aimed to assess IDO activity in relation to risk of IFN-alpha--associated depression in HCV patients.

Methods {#S2}
=======

KYN/TRP ratio (KTR) was used as a marker of IDO activity \[[@R10]\]. Blood samples were collected after 12 hrs of fasting. Serum levels of TRP and KYN were detected by HPLC-UV-fluorometric method \[[@R11]\] in 80 American Caucasian HCV patients awaiting treatment by peg interferon-(IFN-) alpha (Pegasys or Peg Intron) (subcutaneous injections, 120 to 180 μg/week) in combination with ribavirin (1,000 to 1,200 mg/day). Doses were determined by the patients' body weight. Treatment lasted for 6--12 months depending on the virus genotype. Patients were evaluated by psychiatrist, and presence/absence of depression during IFN-alpha treatment was assessed retrospectively (within 2 years after initiation of treatment) by utilization of Structured Clinical Interview for DSM-IV axis 1 Disorders (SCID) for past depression. Study was approved by Tufts Medical Center IRB, and written consents were obtained for participation in the study.

Statistical Analysis {#S3}
====================

Quantitative data are presented using median (50-th percentile) and minimum - maximum range. Non-parametric tests (Kruskal-Wallis test and Chi-square tests) were used to assess statistical significance of the obtained data.

Results {#S4}
=======

There were 56 males and 24 female American Caucasian HCV patients, 55.3 + 7.55 years of age. Sixty four patients had HCV genotype 1 or 4, and sixteen patients had HCV genotype 2 or 3.

Forty three patients experienced depression during IFN-alpha/ribavirin treatment. Patients who developed depression had higher TRP concentrations than patients who did not develop depression (p\<0.05, Kruscal-Wallis test) ([Table 1](#T1){ref-type="table"}).

There were no differences in KYN concentrations and KTR between 43 patients who did and 37 patients who did not experience IFN-alpha--associated depression ([Table 1](#T1){ref-type="table"}).

Odds of development of depression increased as TRP levels elevated from 33% (TRP levels \<12000 pmol/ml) to 68% (TRP levels\>16000 pmol/ml, p\<0.03) ([Table 2](#T2){ref-type="table"}).

Discussion {#S5}
==========

The main finding of our study was an observation that odds of the development of IFN-alpha -- associated depression were increased with elevated concentrations of serum TRP. The present results suggest that high serum TRP level might be a risk factor for the development of IFN-alpha -- associated depression. Recent prospective study did not find differences in TRP serum levels between depressed (Beck Depression Inventory, BDI scores \>10) and non-depressed (BDI\<10) HCV patients at each time point (baseline, one and six months) during IFN-alpha treatment and 3 months post-treatment \[[@R12]\]. Authors did not compare baseline TRP levels in patients who develop and did not develop depression during IFN-alpha therapy. In the present retrospective study plasma TRP levels in HCV patients (not currently undergoing IFN-alpha treatment) were higher in patients who experienced than in those who did not experience depression during past IFN-alpha treatment.

TRP is an initial substrate of serotonin (and other methoxyindoles, i.e., N-acetyl serotonin and melatonin) biosynthesis \[[@R13]\]. Serotonin deficiency was suggested as one of the major mechanisms of depression \[[@R4], [@R5]\]. Availability of TRP as a substrate for serotonin biosynthesis is one of the rate-limiting factors of serotonin formation from TRP \[[@R14]\]. TRP is transported into brain by a competitive carrier system it shares with such other large neutral amino acids such as tyrosine, phenylalanine, leucine, isoleucine, and valine \[[@R14]\]. Elevated serum TRP concentrations might, therefore, reflect the impaired TRP transport via blood-brain-barrier (BBB). Increased serum ratio of large amino acids to TRP, suggesting impaired TRP transport via BBB, was reported in depressed patients \[[@R15]\]. Therefore, present observation of association of elevated concentrations of serum TRP with the odds of development of IFN-alpha -- associated depression is in agreement with the serotonin deficiency hypothesis of depression.

The other rate-limiting factor of serotonin biosynthesis from TRP is the activity of TRPhydroxylase 2 (Tph2), an enzyme catalyzing TRP conversion into serotonin \[[@R16]\]. Clinical and experimental studies suggested the association of depression with Tph2 deficiency \[[@R17]\]. There may be a possibility that elevated serum TRP concentrations are associated with Tph2 deficiency.

We previously reported an association between high producer (T) allele of IFNG (+874) T/A gene with the risk of IFN-alpha -- associated depression \[[@R9]\]. Since IFNG (+874) gene encodes the production of IFNG, the strongest inducer of IDO, we suggested that IDO activity is a risk factor for IFN-alpha -- associated depression. Contrary to our suggestion, we did not find the difference between KTR (as a marker of IDO activity) in patients who develop and who did not develop IFN-alpha -- associated depression. Interpretation of the present results should consider that presence of high producer (T) allele of polymorphic IFNG (+874) gene relates to the possible rate of IFNG production in response to inflammation, and might enable carriers of T allele to produce more IFNG, and, consequently, more KYN from TRP in response to IFN-alpha treatment. However, the studied patients were free from IFN-alpha/ribavirin treatment at the time of blood samples collection. In addition, activation of IDO by IFNG depends on other factors, including polymorphism of IDO gene \[[@R18]\]. KTR characterizes the actual serum concentrations of KYN formed from TRP as a result of IFNG-induced activation of IDO.

Up-regulation of TRP -- KYN metabolism was observed in major depressive disorder \[[@R19]\]. However, some studies indicated that it might occur independently from TRP depletion in depressed patients \[[@R20]\]. Despite many similarities between IFN-alpha--associated depression and major depressive disorder \[[@R2]\], the exposure to chronic viral infection might modify mechanisms of depression development in HCV patients.

Our data warrant the further studies (in a larger population sample) of the relationship between TRP -- serotonin and TRP -- KYN pathways of TRP metabolism as risk factors for depression.

Conclusions {#S6}
===========

Taken together, the results of our previously published \[[@R9]\] and present studies suggest that deficiency of serotonin formation from TRP is a major risk factor for developing of IFN-alpha -- associated depression. The presence of high (T) producer allele of IFNG(+874) gene that encodes the production of IFNG, the strongest IDO inducer, might augment the risk of IFN-alpha -- associated depression, especially in patients with deficient serotonin formation of TRP, by additional decrease of TRP availability as a substrate for serotonin biosynthesis.
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###### 

Kynurenines and risk of IFN-alpha -- associated depression.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                               Depressed (n=43)                                   Non Depressed (n=37)                               P - value (Kruskal-Wallis test)
  -------------------------------------------- -------------------------------------------------- -------------------------------------------------- ---------------------------------
  Tryptophan:\                                 15405 ± 3817.4 [\*](#TFN2){ref-type="table-fn"}\   13646 ± 3634.7 [\*](#TFN2){ref-type="table-fn"}\   0.05
  Mean ± sd[\#](#TFN1){ref-type="table-fn"}\   14500 \< 12500--17900\>                            13100 \< 10600--15900\>                            
  Median \<q1--q3\>                                                                                                                                  

  Kynurenine:\                                 1124.8 ± 464.8 [\*](#TFN2){ref-type="table-fn"}\   1049.7 ± 334.8 [\*](#TFN2){ref-type="table-fn"}\   0.62
  Mean ± sd\                                   1020 \< 860--1330\>                                970 \< 880--1180\>                                 
  Median \<q1--q3\>                                                                                                                                  

  Kynurenine/tryptophan (X100):\               7.4 ± 2.6\                                         7.9 ± 2.5\                                         0.38
  Mean ± sd\                                   6.9 \< 5.65--9.2\>                                 7.6 \< 5.9--9.36\>                                 
  Median \<q1--q3\>                                                                                                                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

sd - standard deviation;

pmol/ml

###### 

Tryptophan level and risk of IFN-alpha -- associated depression.

  Tryptophan level (pmol/ml)   \% of depressed patients,(number of observations, depressed/total)
  ---------------------------- --------------------------------------------------------------------
  \<=12000                     33 % (6/18)
  12001 --14000                52% (11/21)
  14001 -- 16000               54% (7/13)
  16001 -- high                68% (19/28)

Odds Ratio (95% CI) for depression is 1.14 (CI: 1.00--1.30) (per 1000 units); Chi-square = 4.44 (df = 1), p\<0.03
